Dynamic Contrast-Enhanced MRI of Prostate Cancer

  • Anwar R. Padhani
Part of the Medical Radiology book series (MEDRAD)


Prostate Cancer Benign Prostatic Hyperplasia Intensity Modulate Radiation Therapy Magn Reson Image Contrast Agent Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexander AA (1995) To color Doppler image the prostate or not: that is the question. Radiology 195:11–13PubMedGoogle Scholar
  2. Barbier EL, Lamalle L, Decorps M (2001) Methodology of brain perfusion imaging. J Magn Reson Imaging 13:496–520CrossRefPubMedGoogle Scholar
  3. Barke A, l'yasov KA, Kiselev VG et al (2003) Dynamic gadolinium-enhanced MR imaging for radiation therapy monitoring in prostate cancer patients. Proceedings of the International Society of Magnetic Resonance in Medicine, 11th scientific meeting, Toronto, p 1463Google Scholar
  4. Beerlage HP, Thuroff S, Madersbacher S et al (2000) Current status of minimally invasive treatment options for localized prostate carcinoma. Eur Urol 37:2–13CrossRefPubMedGoogle Scholar
  5. Benjamin LE, Golijanin D, Itin A et al (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159–165PubMedGoogle Scholar
  6. Bettencourt MC, Bauer JJ, Sesterhenn IA et al (1998) CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 160:459–465CrossRefPubMedGoogle Scholar
  7. Bezzi M, Kressel HY, Allen KS et al (1988) Prostatic carcinoma: staging with MR imaging at 1.5 T. Radiology 169:339–346PubMedGoogle Scholar
  8. Bigler SA, Deering RE, Brawer MK (1993) Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24:220–226CrossRefPubMedGoogle Scholar
  9. Boni RA, Sulser T, Jochum W et al (1997) Laser ablationinduced changes in the prostate: findings at endorectal MR imaging with histologic correlation. Radiology 202:232–236PubMedGoogle Scholar
  10. Borre M, Offersen BV, Nerstrom B et al (1998) Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78:940–944PubMedGoogle Scholar
  11. Bostwick DG (2000) Immunohistochemical changes in prostate cancer after androgen deprivation therapy. Mol Urol 4:101–106PubMedGoogle Scholar
  12. Bostwick DG, Iczkowski KA (1998) Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin Urol Oncol 16:118–123PubMedGoogle Scholar
  13. Bostwick DG, Wheeler TM, Blute M et al (1996) Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 48:47–57CrossRefPubMedGoogle Scholar
  14. Bostwick DG, Grignon DJ, Hammond ME et al (2000) Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:995–1000PubMedGoogle Scholar
  15. Brawer MK, Deering RE, Brown M et al (1994) Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73:678–687PubMedGoogle Scholar
  16. Bree RL (1997) The role of color Doppler and staging biopsies in prostate cancer detection. Urology 49:31–34PubMedGoogle Scholar
  17. Brix G, Semmler W, Port R et al (1991) Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15:621–628PubMedGoogle Scholar
  18. Brookes JA, Redpath TW, Gilbert FJ et al (1996) Measurement of spin-lattice relaxation times with FLASH for dynamic MRI of the breast. Br J Radiol 69:206–214PubMedGoogle Scholar
  19. Brown G, Macvicar DA, Ayton V et al (1995) The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma. Clin Radiol 50:601–606PubMedGoogle Scholar
  20. Buckley DL, Kerslake RW, Blackband SJ et al (1994) Quantitative analysis of multi-slice Gd-DTPA enhanced dynamic MR images using an automated simplex minimization procedure. Magn Reson Med 32:646–651PubMedGoogle Scholar
  21. Carter HB, Brem RF, Tempany CM et al (1991) Nonpalpable prostate cancer: detection with MR imaging. Radiology 178:523–525PubMedGoogle Scholar
  22. Chen M, Hricak H, Kalbhen CL et al (1996) Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. AJR Am J Roentgenol 166:1157–1163PubMedGoogle Scholar
  23. Cho JY, Kim SH, Lee SE (1998) Diffuse prostatic lesions: role of color Doppler and power Doppler ultrasonography. J Ultrasound Med 17:283–287PubMedGoogle Scholar
  24. Civantos F, Soloway MS, Pinto JE (1996) Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 14:22–31PubMedGoogle Scholar
  25. Clements R (2001) Ultrasonography of prostate cancer. Eur Radiol 11:2119–2125CrossRefPubMedGoogle Scholar
  26. CRC (2001) Cancer research campaign scientific handbook 2000–2002. Cancer Research Campaign, London, UKGoogle Scholar
  27. Crone C (1963) The permeability of capillaries in various organs as determined by the use of ‚indicator diffusion’ method. Acta Physiol Scand 58:292–305PubMedGoogle Scholar
  28. Daldrup HE, Shames DM, Husseini W et al (1998) Quantification of the extraction fraction for gadopentetate across breast cancer capillaries. Magn Reson Med 40:537–543PubMedGoogle Scholar
  29. D'Amico AV, Whittington R, Schnall M et al (1995) The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer. Cancer 75:2368–2372PubMedGoogle Scholar
  30. Deering RE, Bigler SA, Brown M et al (1995) Microvascularity in benign prostatic hyperplasia. Prostate 26:111–115PubMedGoogle Scholar
  31. Donahue KM, Burstein D, Manning WJ et al (1994) Studies of Gd-DTPA relaxivity and proton exchange rates in tissue. Magn Reson Med 32:66–76PubMedGoogle Scholar
  32. Duque JL, Loughlin KR, Adam RM et al (1999) Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54:523–527PubMedGoogle Scholar
  33. Dvorak HF, Brown LF, Detmar M et al (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039Google Scholar
  34. Eberhard A, Kahlert S, Goede V et al (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60:1388–1393PubMedGoogle Scholar
  35. Engelbrecht MR, Huisman HJ, Laheij RJ et al (2003) Discrimination of peripheral zone and central gland prostate cancer from normal prostatic tissue using dynamic contrast-enhanced MR imaging. Radiology 229:248–54PubMedGoogle Scholar
  36. EUCAN Cancer Incidence, mortality and prevalence in the European Union (1996 estimates)Google Scholar
  37. Ferrer FA, Miller LJ, Andrawis RI et al (1998) Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51:161–167CrossRefGoogle Scholar
  38. Flickinger FW, Allison JD, Sherry RM et al (1993) Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. Magn Reson Imaging 11:617–620CrossRefPubMedGoogle Scholar
  39. Frauscher F, Klauser A, Halpern EJ et al (2001) Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet 357:1849–1850CrossRefPubMedGoogle Scholar
  40. Frauscher F, Klauser A, Volgger H et al (2002) Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J Urol 167:1648–1652CrossRefPubMedGoogle Scholar
  41. Fregene TA, Khanuja PS, Noto AC et al (1993) Tumor-associated angiogenesis in prostate cancer. Anticancer Res 13:2377–2381PubMedGoogle Scholar
  42. Gettman MT, Pacelli A, Slezak J et al (1999) Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology 54:479–485PubMedGoogle Scholar
  43. Gibbs P, Young BJ, Turnbull LS (2001) Diagnostic utility of perfusion weighted imaging of the prostate. Proceeding of the UK Radiological Congress, LondonGoogle Scholar
  44. Greenlee RT, Hill-Harmon MB, Murray T et al (2001) Cancer statistics 2001. CA Cancer J Clin 51:15–36PubMedGoogle Scholar
  45. Gribbestad IS, Nilsen G, Fjosne HE et al (1994) Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography. J Magn Reson Imaging 4:477–480PubMedGoogle Scholar
  46. Haggstrom S, Lissbrant IF, Bergh A et al (1999) Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J Urol 161:1620–1625CrossRefPubMedGoogle Scholar
  47. Hall MC, Troncoso P, Pollack A et al (1994) Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 44:869–875CrossRefPubMedGoogle Scholar
  48. Harvey CJ, Blomley MJ, Dawson P et al (2001) Functional CT imaging of the acute hyperemic response to radiation therapy of the prostate gland: early experience. J Comput Assist Tomogr 25:43–49CrossRefPubMedGoogle Scholar
  49. Hawighorst H, Knapstein PG, Knopp MV et al (1998) Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 58:3598–3602PubMedGoogle Scholar
  50. Hoffmann U, Brix G, Knopp MV et al (1995) Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 33:506–514PubMedGoogle Scholar
  51. Hricak H, Dooms GC, McNeal JE et al (1987) MR imaging of the prostate gland: normal anatomy. AJR Am J Roentgenol 148:51–58PubMedGoogle Scholar
  52. Huber P, Peschke P, Brix G et al (1999) Synergistic interaction of ultrasonic shock waves and hyperthermia in the Dunning prostate tumor R3327-AT1. Int J Cancer 82:84–91CrossRefPubMedGoogle Scholar
  53. Huch Boni RA, Boner JA, Lutolf UM et al (1995a) Contrast-enhanced endorectal coil MRI in local staging of prostate carcinoma. J Comput Assist Tomogr 19:232–237PubMedGoogle Scholar
  54. Huch Boni RA, Trinkler F, Pestalozzi D et al (1995b) The value of high resolution MRI for diagnosis of recurrent prostate cancer. Proceedings of the Society of Magnetic Resonance, 3rd scientific meeting, NiceGoogle Scholar
  55. Huisman HJ, Engelbrecht MR, Barentsz JO (2001) Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging 13:607–614CrossRefPubMedGoogle Scholar
  56. Husband JE, Padhani AR, MacVicar AD et al (1998) Magnetic resonance imaging of prostate cancer: comparison of image quality using endorectal and pelvic phased array coils. Clin Radiol 53:673–681PubMedGoogle Scholar
  57. Ito H, Kamoi K, Yokoyama K et al (2003) Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasonography. Br J Radiol 76:617–24CrossRefPubMedGoogle Scholar
  58. Izawa JI, Dinney CP (2001) The role of angiogenesis in prostate and other urologic cancers: a review. CMAJ 164:662–670PubMedGoogle Scholar
  59. Jackson MW, Bentel JM, Tilley WD (1997) Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157:2323–2328PubMedGoogle Scholar
  60. Jager GJ, Ruijter ET, van de Kaa CA et al (1996) Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol 166:845–852PubMedGoogle Scholar
  61. Jager GJ, Ruijter ET, van de Kaa CA et al (1997) Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 203:645–652PubMedGoogle Scholar
  62. Jain RK, Safabakhsh N, Sckell A et al (1998) Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 95:10820–10825CrossRefPubMedGoogle Scholar
  63. Joseph IB, Nelson JB, Denmeade SR et al (1997) Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 3:2507–2511PubMedGoogle Scholar
  64. Kahn T, Burrig K, Schmitz-Drager B et al (1989) Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation. Radiology 173:847–851PubMedGoogle Scholar
  65. Kaiser WA, Zeitler E (1989) MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 170:681–686PubMedGoogle Scholar
  66. Kurhanewicz J, Vigneron DB, Hricak H et al (1996) Threedimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 198:795–805PubMedGoogle Scholar
  67. Lee F, Torp-Pedersen S, Littrup PJ et al (1989) Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen. Radiology 170:29–32PubMedGoogle Scholar
  68. Leibel SA, Fuks Z, Zelefsky MJ et al (2002) Intensity-modulated radiotherapy. Cancer J 8:164–176PubMedGoogle Scholar
  69. Lencioni R, Menchi I, Paolicchi A et al (1997) Prediction of pathological tumor volume in clinically localized prostate cancer: value of endorectal coil magnetic resonance imaging. Magma 5:117–121PubMedGoogle Scholar
  70. Levine AC, Liu XH, Greenberg PD et al (1998) Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139:4672–4678CrossRefPubMedGoogle Scholar
  71. Liney GP, Turnbull LW, Knowles AJ (1999) In vivo magnetic resonance spectroscopy and dynamic contrast enhanced imaging of the prostate gland. NMR Biomed 12:39–44CrossRefPubMedGoogle Scholar
  72. Ling CC, Humm J, Larson S et al (2000) Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47:551–560CrossRefPubMedGoogle Scholar
  73. Lovett K, Rifkin MD, McCue PA et al (1992) MR imaging characteristics of noncancerous lesions of the prostate. J Magn Reson Imaging 2:35–39PubMedGoogle Scholar
  74. Matsushima H, Goto T, Hosaka Y et al (1999) Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 85:1822–1827CrossRefPubMedGoogle Scholar
  75. McSherry SA, Levy F, Schiebler ML et al (1991) Preoperative prediction of pathological tumor volume and stage in clinically localized prostate cancer: comparison of digital rectal examination, transrectal ultrasonography and magnetic resonance imaging. J Urol 146:85–89PubMedGoogle Scholar
  76. Meyer GE, Yu E, Siegal JA et al (1995) Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 76:2304–2311PubMedGoogle Scholar
  77. Mirowitz SA, Brown JJ, Heiken JP (1993) Evaluation of the prostate and prostatic carcinoma with gadolinium-enhanced endorectal coil MR imaging. Radiology 186:153–157PubMedGoogle Scholar
  78. Moul JW (1999) Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 35:399–407CrossRefPubMedGoogle Scholar
  79. Mueller-Lisse UG, Vigneron DB, Hricak H et al (2001) Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 221:380–390PubMedGoogle Scholar
  80. Murphy WM, Soloway MS, Barrows GH (1991) Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68:821–828PubMedGoogle Scholar
  81. Nakashima J, Imai Y, Tachibana M et al (1997) Effects of endocrine therapy on the primary lesion in patients with prostate carcinoma as evaluated by endorectal magnetic resonance imaging. Cancer 80:237–241CrossRefPubMedGoogle Scholar
  82. Namimoto T, Morishita S, Saitoh R et al (1998) The value of dynamic MR imaging for hypointensity lesions of the peripheral zone of the prostate. Comput Med Imaging Graph 22:239–245CrossRefPubMedGoogle Scholar
  83. Newman JS, Bree RL, Rubin JM (1995) Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site. Radiology 195:86–90PubMedGoogle Scholar
  84. Noseworthy MN, Morton G, Wright GA (1999) Comparison of normal and cancerous prostate using dynamic Tl and T2* weighted MRI. Proceedings of the 7th annual meeting of the international society for magnetic resonance in medicine, PhiladelphiaGoogle Scholar
  85. Nutting CM, Convery DJ, Cosgrove VP et al (2000) Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 48:649–656CrossRefPubMedGoogle Scholar
  86. Nutting CM, Corbishley CM, Sanchez-Nieto B et al (2002) Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. Br J Radiol 75:151–161PubMedGoogle Scholar
  87. Offersen BV, Borre M and Overgaard J (1998) Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. Apmis 106:463–469PubMedGoogle Scholar
  88. Ogura K, Maekawa S, Okubo K et al (2001) Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. Urology 57:721–726CrossRefPubMedGoogle Scholar
  89. Okihara K, Miki T, Joseph Babaian R (2002) Clinical efficacy of prostate cancer detection using power Doppler imaging in American and Japanese men. J Clin Ultrasound 30:213–221CrossRefPubMedGoogle Scholar
  90. Osman YM, Larson TR, El-Diasty T et al (2000) Correlation between central zone perfusion defects on gadolinium-enhanced MRI and intraprostatic temperatures during transurethral microwave thermotherapy. J Endourol 14:761–766PubMedGoogle Scholar
  91. Outwater E, Schiebler ML, Tomaszewski JE et al (1992) Mucinous carcinomas involving the prostate: atypical findings at MR imaging. J Magn Reson Imaging 2:597–600PubMedGoogle Scholar
  92. Padhani AR (2002) Dynamic contrast-enhanced MRI in clinical oncology-current status and future directions. J Magn Reson Imaging 16:407–422CrossRefPubMedGoogle Scholar
  93. Padhani AR, Khoo VS, Suckling J et al (1999) Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Oncol Biol Phys 44:525–533CrossRefPubMedGoogle Scholar
  94. Padhani AR, Gapinski CJ, Macvicar DA et al (2000) Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 55:99–109PubMedGoogle Scholar
  95. Padhani AR, MacVicar AD, Gapinski CJ et al (2001) Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology 218:365–374PubMedGoogle Scholar
  96. Padhani AR, Parker C, Norman A et al (2002) Dynamic contrast-enhanced MRI of prostate cancer for predicting patient outcome. Proceedings of the International Society of Magnetic Resonance in Medicine, 10th Scientific meeting, HonululuGoogle Scholar
  97. Parker GJ, Tofts PS (1999) Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging. Top Magn Reson Imaging 10:130–142CrossRefPubMedGoogle Scholar
  98. Parker GJ, Suckling J, Tanner SF et al (1997) Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 7:564–574PubMedGoogle Scholar
  99. Parker GJ, Suckling J, Tanner SF et al (1998) MRIW: parametric analysis software for contrast-enhanced dynamic MR imaging in cancer. Radiographics 18:497–506PubMedGoogle Scholar
  100. Parker GJ, Baustert I, Tanner SF et al (2000) Improving image quality and T(1) measurements using saturation recovery turboFLASH with an approximate K-space normalisation filter. Magn Reson Imaging 18:157–167CrossRefPubMedGoogle Scholar
  101. Patel U, Rickards D (1994) The diagnostic value of colour Doppler flow in the peripheral zone of the prostate, with histological correlation. Br J Urol 74:590–595PubMedGoogle Scholar
  102. Phillips ME, Kressel HY, Spritzer CE et al (1987) Normal prostate and adjacent structures: MR imaging at 1.5 T. Radiology 164:381–385PubMedGoogle Scholar
  103. Pinault S, Tetu B, Gagnon J et al (1992) Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide. Urology 39:254–261CrossRefPubMedGoogle Scholar
  104. Quinn SF, Franzini DA, Demlow TA et al (1994) MR imaging of prostate cancer with an endorectal surface coil technique: correlation with whole-mount specimens. Radiology 190:323–327PubMedGoogle Scholar
  105. Quint LE, van Erp JS, Bland PH et al (1991) Carcinoma of the prostate: MR images obtained with body coils do not accurately reflect tumor volume. AJR Am J Roentgenol 156:511–516PubMedGoogle Scholar
  106. Rifkin MD, Zerhouni EA, Gatsonis CA et al (1990) Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med 323:621–626PubMedGoogle Scholar
  107. Rosen BR, Belliveau JW, Buchbinder BR et al (1991) Contrast agents and cerebral hemodynamics. Magn Reson Med 19:285–292PubMedGoogle Scholar
  108. Rosenman J (2001) Incorporating functional imaging information into radiation treatment. Semin Radiat Oncol 11:83–92CrossRefPubMedGoogle Scholar
  109. Rubin MA, Buyyounouski M, Bagiella E et al (1999) Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 53:542–547CrossRefPubMedGoogle Scholar
  110. Sanders H, El-Galley R (1997) Ultrasound findings are not useful for defining stage T1c prostate cancer. World J Urol 15:336–338CrossRefPubMedGoogle Scholar
  111. Schiebler ML, Tomaszewski JE, Bezzi M et al (1989) Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. Radiology 172:131–137PubMedGoogle Scholar
  112. Schnall MD, Imai Y, Tomaszewski J et al (1991) Prostate cancer: local staging with endorectal surface coil MR imaging. Radiology 178:797–802PubMedGoogle Scholar
  113. Secaf E, Nuruddin RN, Hricak H et al (1991) MR imaging of the seminal vesicles. AJR Am J Roentgenol 156:989–994PubMedGoogle Scholar
  114. Shearer RJ, Davies JH, Gelister JS et al (1992) Hormonal cyto-reduction and radiotherapy for carcinoma of the prostate. Br J Urol 69:521–524PubMedGoogle Scholar
  115. Silberman MA, Partin AW, Veltri RW et al (1997) Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79:772–779CrossRefPubMedGoogle Scholar
  116. Smith DM, Murphy WM (1994) Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer 73:1472–1477PubMedGoogle Scholar
  117. Smith DS, Catalona WJ, Herschman JD (1996) Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 276:1309–1315CrossRefPubMedGoogle Scholar
  118. Sommer FG, McNeal JE, Carrol CL (1986) MR depiction of zonal anatomy of the prostate at 1.5 T. J Comput Assist Tomogr 10:983–989PubMedGoogle Scholar
  119. Sommer FG, Nghiem HV, Herfkens R et al (1993) Determining the volume of prostatic carcinoma: value of MR imaging with an external-array coil. AJR Am J Roentgenol 161:81–86PubMedGoogle Scholar
  120. Sorensen AG, Tievsky AL, Ostergaard L et al (1997) Contrast agents in functional MR imaging. J Magn Reson Imaging 7:47–55PubMedGoogle Scholar
  121. Strohmeyer D, Rossing C, Bauerfeind A et al (2000) Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 45:216–224CrossRefPubMedGoogle Scholar
  122. Swanson MG, Vigneron DB, Tran TK et al (2001) Magnetic resonance imaging and spectroscopic imaging of prostate cancer. Cancer Invest 19:510–523CrossRefPubMedGoogle Scholar
  123. Takeda M, Akiba H, Yama N et al (2002) Value of multi-sectional fast contrast-enhanced MR imaging in patients with elevated PSA levels after radical prostatectomy. American Roentgen Ray Society, Atlanta. Am J Roentgenol 178(S):97Google Scholar
  124. Tanaka N, Samma S, Joko M et al (1999) Diagnostic usefulness of endorectal magnetic resonance imaging with dynamic contrast-enhancement in patients with localized prostate cancer: mapping studies with biopsy specimens. Int J Urol 6:593–599CrossRefPubMedGoogle Scholar
  125. Taylor JS, Reddick WE (2000) Evolution from empirical dynamic contrast-enhanced magnetic resonance imaging to pharmacokinetic MRI. Adv Drug Deliv Rev 41:91–110CrossRefPubMedGoogle Scholar
  126. Thornbury JR, Ornstein DK, Choyke PL et al (2001) Prostate cancer: what is the future role for imaging? AJR Am J Roentgenol 176:17–22PubMedGoogle Scholar
  127. Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7:91–101PubMedGoogle Scholar
  128. Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232CrossRefPubMedGoogle Scholar
  129. Turnbull LW, Buckley DL, Turnbull LS et al (1999) Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA-enhanced MR imaging and histopathology. J Magn Reson Imaging 9:311–316CrossRefPubMedGoogle Scholar
  130. Van Dorsten F, Engelbrecht MR, Van de graaf JJ et al (2001) Combined dynamic contrast-enhanced MRI and 1H MR spectroscopy may differentiate prostate carcinoma from chronic prostatitis. Radiology 211(P):585Google Scholar
  131. Vigneron DB, Males RG, Noworolski S et al (1998) 3D MRSI of prostate cancer: correlation with histologic grade. Proceedings of the international society for magnetic resonance in medicine, 6th scientific meeting, SidneyGoogle Scholar
  132. Walsh K, Sherwood RA, Dew TK et al (1999) Angiogenic peptides in prostatic disease. BJU Int 84:1081–1083CrossRefPubMedGoogle Scholar
  133. Wefer AE, Hricak H, Vigneron DB et al (2000) Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 164:400–404CrossRefPubMedGoogle Scholar
  134. Weidner N, Carroll PR, Flax J et al (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401–409PubMedGoogle Scholar
  135. Weingartner K, Ben-Sasson SA, Stewart R et al (1998) Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: an in vitro model for assessment. J Urol 159:465–470PubMedGoogle Scholar
  136. Yu KK, Scheidler J, Hricak H et al (1999) Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 213:481–488PubMedGoogle Scholar
  137. Zelefsky MJ, Fuks Z, Happersett L et al (2000) Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55:241–249CrossRefPubMedGoogle Scholar
  138. Zhong H, De Marzo AM, Laughner E et al (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830–5835PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Anwar R. Padhani
    • 1
  1. 1.Paul Strickland Scanner CentreMount Vernon HospitalNorthwood, MiddlesexUK

Personalised recommendations